Despite the significant therapeutic response achieved with BCMA CAR T cell therapy, MM remains a highly heterogeneous tumor, and thus mono-targeted CAR T therapy may be susceptible to immunologic escape from BCMA-negative cells over the long term25. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.